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http://www.biomedcentral.com/1472-6947/14/87RESEARCH ARTICLE Open AccessCan multiple SNP testing in BRCA2 and BRCA1
female carriers be used to improve risk prediction
models in conjunction with clinical assessment?
Mattia CF Prosperi1*, Sarah L Ingham1, Anthony Howell2, Fiona Lalloo3, Iain E Buchan1 and Dafydd Gareth Evans2,3Abstract
Background: Several single nucleotide polymorphisms (SNPs) at different loci have been associated with breast
cancer susceptibility, accounting for around 10% of the familial component. Recent studies have found direct
associations between specific SNPs and breast cancer in BRCA1/2 mutation carriers. Our aim was to determine
whether validated susceptibility SNP scores improve the predictive ability of risk models in comparison/conjunction
to other clinical/demographic information.
Methods: Female BRCA1/2 carriers were identified from the Manchester genetic database, and included in the
study regardless of breast cancer status or age. DNA was extracted from blood samples provided by these women
and used for gene and SNP profiling. Estimates of survival were examined with Kaplan-Meier curves. Multivariable
Cox proportional hazards models were fit in the separate BRCA datasets and in menopausal stages screening different
combinations of clinical/demographic/genetic variables. Nonlinear random survival forests were also fit to identify
relevant interactions. Models were compared using Harrell’s concordance index (1 - c-index).
Results: 548 female BRCA1 mutation carriers and 523 BRCA2 carriers were identified from the database. Median
Kaplan-Meier estimate of survival was 46.0 years (44.9-48.1) for BRCA1 carriers and 48.9 (47.3-50.4) for BRCA2. By fitting
Cox models and random survival forests, including both a genetic SNP score and clinical/demographic variables,
average 1 - c-index values were 0.221 (st.dev. 0.019) for BRCA1 carriers and 0.215 (st.dev. 0.018) for BRCA2 carriers.
Conclusions: Random survival forests did not yield higher performance compared to Cox proportional hazards. We
found improvement in prediction performance when coupling the genetic SNP score with clinical/demographic
markers, which warrants further investigation.
Keywords: Breast cancer, BRCA1, BRCA2, Single nucleotide polymorphism, Cox regression, Random survival forests,
Survival analysis, Prognostic model, Concordance indexBackground
BRCA1 and BRCA2 are major susceptibility genes that
confer high lifetime risks for both breast and ovarian
cancer. Deleterious mutations in these autosomal dom-
inant cancer genes account for approximately 15-20% of
the familial component of breast cancer [1-3]. The vari-
able penetrance exhibited by these BRCA mutations sug-
gest other genetic factors to be present [4], and several
studies have now identified a large number of breast* Correspondence: mattia.prosperi@manchester.ac.uk
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unless otherwise stated.cancer susceptibility alleles [5-7]. Genome association
studies had identified until recently 19 common variants
at 18 loci that are associated with breast cancer suscepti-
bility [5,7] though the risk attributed to each of these sin-
gle nucleotide polymorphisms (SNPs) are often modest
and largely remain unexplained [6]. More recent studies
into these polymorphisms have found direct associations
between specific SNPs and breast cancer in BRCA1/2 mu-
tation carriers; TOX3, FGFR2, MAP3K, LSP1, 2q35,
SLC4A7, 1p11.2, 5p12, 6q25.1 loci have all been associated
with increased risk in breast cancer for BRCA2 mutation
carriers [6,7]. Antoniou et al. [6] further determined
TOX3, 2q35, and 6q25.1 were polymorphisms thatl Ltd. This is an Open Access article distributed under the terms of the Creative
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recent study by Ingham et al. [8] found the 18 validated
breast cancer susceptibility SNPs do not differentiate the
risks of breast cancer in those with BRCA1 mutations.
Some genetic modifiers may in themselves influence
breast cancer risk factors rather than be directly associ-
ated; such as the genetic component associated with high
mammographic density [4,9]. A recent study by Mitchell
et al. looking at mammographic density in 206 BRCA1
and BRCA2 carriers compared to non-carriers found a
significant association between increased breast cancer
risk and increasing density in BRCA1/2 carriers [9].
Alongside risk factors with a genetic component there
are several hormonal risk factors that are thought to be
associated with breast cancer both among the general
population and those with hereditary breast cancer [10].
Correlations have been made between changes in breast
mitotic/apoptotic activity and alterations in hormone
levels across the menstrual cycle, and that if the levels of
oestrogen and progesterone are reduced then the risk of
breast cancer is reduced [11,12]. Though some debate
surrounds the association of these factors with breast
cancer among BRCA1/2 carriers, with studies finding an
association only in BRCA1 mutation carriers [13] and
other finding no association [12]. Modifiable factors, such
as body mass index (BMI) are also thought to influence
the risk of breast cancer. Obesity has a well-documented
association with breast cancer in the general population,
due to influence of biological pathways [14], and postmen-
opausal weight gain has been associated with increased
risk among BRCA carriers [15].
At present, several personalised risk prediction models
have been developed using familial, demographic, clinical,
laboratory, genetic information domains, with a few com-
binations thereof [8,16-19], as for instance the Gail, BOA-
DICEA or IBIS methods [20], as well as more specific
studies as surveys on gene expression markers [21], and
use of machine learning for predicting recurrence or
re-defying subtypes [22,23].
The aim of this study was to determine whether vali-
dated susceptibility SNPs improve the predictive ability
of risk models in conjunction and comparison to demo-
graphic and clinical information.
Methods
Study population
Patients included in this study were BRCA1 and BRCA2
female pathogenic mutation carriers ascertained from
the Genetic Medicine department, St Mary’s Hospital,
Manchester, UK. This clinic is one of the largest specialist
genetics departments within the UK, and all families with
a history of breast or ovarian cancer within the North
West region are referred. Patients were included in this
study regardless of breast cancer status or age. Dates ofbirth were taken from the information collected at time of
family referral to the genetics department. Cases of breast
cancer were confirmed by means of hospital records or
the North West Cancer Intelligence Service. Dates of last
follow-up were either date of breast cancer diagnosis or
date the woman was last in contact with the genetics
department or other NHS service or date of death.
Ethics statement
This research has been performed in accordance with the
Declaration of Helsinki. The NHS Health Research
Authority, National Health Research Ethics Committee
North West, Greater Manchester Central (Barlow House,
4 Minshull Street, Manchester, M1 3DZ), reviewed this
study and gave ethical approval; the Research Ethics Com-
mittee reference number is 10/H1008/24, dated 11th July
2013. Written informed consent was obtained from all
study participants (none minor at the time of enrolment).
DNA testing
DNA was extracted from blood samples provided by
women attending the genetic clinics, using DNA Sanger
sequencing and multiplex ligation-dependent probe ampli-
fication analysis for gene and SNP profiling; BRCA1 and
BRCA2 mutations were identified as well as the presence of
any of the 18 tested breast cancer SNPs. Overall breast can-
cer SNP risk scores were calculated for each woman using
the methods as recorded in the article Ingham et al. [8].
Statistical models
The study population was stratified by BRCA type (1 or 2)
and menopausal stage (ovulating vs. menopause). Inci-
dence of breast cancer was calculated for the strata, as
well as Kaplan-Meier [24] estimates of survival. Main-
effect multivariable Cox proportional hazards (CPH) [25]
models were fit in the separate BRCA data sets and then
in the menopausal stages. End-point was the time to can-
cer, censored by the current age (or loss to follow up, or
death for other causes). Proportional hazards assumption
was tested via weighted residuals [26]. Variables included
in the analyses were (see Table 1): year of birth, Manches-
ter score [27] (transformed using the inverse hyperbolic
sine), BMI; parity; age of menarche; age of menopause;
age of first full-term pregnancy; oral contraception usage;
time of diagnosis of an ovarian cancer followed up by oo-
phorectomy (if any); time of mastectomy (if any); SNPs
rs614367, rs704010, rs713588, rs889312, rs909116,
rs1011970, rs1156287, rs1562430, rs2981579, rs3757318,
rs3803662, rs4973768, rs8009944, rs9790879, rs10995190,
rs11249433, rs13387042, rs10931936, genetic predispos-
ition score (GPS), calculated on the mentioned SNPs
according to Ingham et al. [8] Missing values were prelim-
inarily analysed by means of univariable CPH, comparing
Akaike information criterion (AIC) [28] and coefficient p-
Table 1 List of variables used in the study (for both BRCA1 and BRCA2 populations), data types, and variable inclusion
in Cox proportional hazards models (i) to (vi)
Variable Data type Model (i) Model (ii) Model (iii) Model (iv) Model (v) Model (vi)
Genetic predisposition score (GPS) Numeric ✓ ✓ ✓
Year of birth Numeric ✓ ✓ ✓ ✓
Manchester score Numeric (inverse
hyperbolic sine scale)
✓ ✓ ✓ ✓
Body mass index (BMI) Numeric ✓ ✓ ✓ ✓
Parity Quartiles (q1 … q4) +
missing category
✓ ✓ ✓ ✓
Age of menarche Quartiles (q1 … q4) +
missing category
✓ ✓ ✓ ✓
Age of menopause Quartiles (q1 … q4) +
missing category +
ovulating stratum
✓ ✓ ✓ ✓
Age of first full-term pregnancy Quartiles (q1 … q4) +
missing category +
never had full term
pregnancy
✓ ✓ ✓ ✓
Oral contraception usage Quartiles (q1 … q4) ✓ ✓ ✓ ✓
Oophorectomy Binary (yes vs. no) ✓ ✓ ✓ ✓
Mastectomy Binary (yes vs. no) ✓ ✓ ✓ ✓
Individual single nucleotide polymorphisms
(SNPs, rs614367, rs704010, rs713588, rs889312,
rs909116, rs1011970, rs1156287, rs1562430,
rs2981579, rs3757318, rs3803662, rs4973768,
rs8009944, rs9790879, rs10995190, rs11249433,
rs13387042, rs10931936)
Binary (yes vs. no) ✓ ✓ ✓
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fication into quartiles and addition of a category for those
values which were missing. The following CPH models
were fit for each population stratum: (i) GPS; (ii) GPS +
year of birth +Manchester score + BMI + parity + age of
menarche + age of menopause + age of full-term preg-
nancy + oral contraception usage + oophorectomy +mast-
ectomy; (iii) SNPs; (iv) SNPs + year of birth +Manchester
score + BMI + parity + age of menarche + age of meno-
pause + age of full-term pregnancy + oral contraception
usage + oophorectomy +mastectomy; (v) year of birth +
Manchester score + BMI + parity + age of menarche + age
of menopause + age of full-term pregnancy + oral contra-
ception usage + oophorectomy +mastectomy; (vi) all vari-
ables. CPH models (ii), (iii), (iv) and (vi) were feature-
selected using a forward/backward stepwise heuristic driven
by AIC [29]. Nonlinear random survival forests (RSF) [30]
were also fit on all variables to identify putative variable in-
teractions (333 trees, choosing the log-rank splitting rule).
Table 1 summarises which variables were used for each
model. CPH and RSF were compared using the comple-
mentary value of Harrell’s concordance index (1 - c-index)
[31] and the area under the receiver operating characteristic
(AUROC) [32], under a bootstrap-based (100 resampled
sets, using the out-of-bag predictions) method of extra-
sample error estimation [33].All analyses were carried out using the R software [34].Results
The BRCA1 population included 548 subjects, whilst the
BRCA2 population 523. Table 2 shows population charac-
teristics stratified by BRCA type and menopausal stage.
Incidence of breast cancer for all BRCA1 carriers was 321
events per 23,649 person-years of follow-up (PYFY), i.e.
0.014 (95% confidence interval, CI 0.012 0.015). It was 92/
9,872 (0.009, 95% CI 0.008-0.011) and 88/3,770 (0.023, 95%
CI 0.019-0.029) for menopause and ovulating strata, re-
spectively. The median (95% CI) Kaplan-Meier estimate of
survival time to breast cancer was 46.0 (44.9-48.1) years in
the whole BRCA1 population, 53.7 (52.0-60.7) for
menopause stratum, and 35.5 (32.9-38.3) for the ovulating
population (p < 0.0001, log-rank test). Women diagnosed
with an ovarian cancer who underwent an oophorectomy
had a higher survival probability than those who did not
(p < 0.0001, log-rank test). At age 50 years, probability
(95% CI) of survival was 0.82 (0.70-0.96) for those who
had oophorectomy (71 women, 12 breast cancer events),
versus 0.34 (0.30-0.39) for the others. At age 60 it was 0.59
(0.40-0.86) versus 0.19 (0.15-0.24). There was one case of
breast cancer after risk reducing mastectomy (out of 49
women operated).
Table 2 Characteristics of the study population
Variable





(n = 113) All (n = 548)*
Menopause
(n = 195) Ovulating (n = 93) All (n = 523)*
Year of birth 1955 (1946-1962) 1963 (1952-1979) 1959 (1948-1969) 1952 (1944-1959) 1963 (1952-1971) 1957 (1947-1966)














Parity 2 (2-3) 1 (0-2) 2 (1-3) 2 (0-9) 2 (0-9) 2 (0-9)
Age of menarche 13 (12-14.25) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14) 13 (12-14)
Age of menopause 43 (38-46) 44 (40-48)** 43 (39-47)** 45 (40.5-48.5) 45 (39.5-49.5)** 45 (40-49)**
Age of full-term
pregnancy
24 (21-28) 23 (20-26.25) 24 (21-28) 24 (21-28) 23 (20.25-27) 24 (21-28)
Oral contraception
usage
5 (1-10) 7 (2.75-11) 5 (2-10) 5 (1-10) 5 (1-10) 5 (1-10)
Genetic
predisposition score
0.98 (0.70-1.29) 0.95 (0.63-1.17) 0.95 (0.67-1.27) 0.83 (0.63-1.17) 1.17 (0.77-1.62) 0.90 (0.68- 1.33)
Oophorectomy 70 (35%) 0 (0%) 71 (12.96%) 88 (45.13%) 0 (0%) 102 (19.50%)





30.83 (28.0-38.90) 41.26 (35.83-49.38) 50.68 (44.77-57.70) 33.66 (29.13-42.49) 44.37 (38.02-51.78)
No. of events 92 (46.00%) 88 (77.88%) 321 (58.58%) 105 (53.85%) 72 (77.42%) 323 (61.76%)
*includes also women with unknown menopausal stage status.
**women may have had menopause after a breast cancer diagnosis.
Figure 1 Kaplan-Meier estimates of being cancer-free for BRCA1 (upper panels) and BRCA2 (lower panels) carriers: overall, stratified by
menopausal stage, and by oophorectomy.
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http://www.biomedcentral.com/1472-6947/14/87Incidence of cancer for all BRCA2 carriers was 323
events per 23,796 person-years of follow-up (PYFY), i.e.
0.014 (95% confidence interval, CI 0.012 0.015). It was
105/10,120 (0.010, 95% CI 0.008-0.012) and 72/3,265
(0.022, 95% CI 0.017- 0.028) for menopause and ovulating
strata, respectively. The median (95% CI) Kaplan-Meier
estimate of survival time was 48.9 (47.3-50.4) years in the
whole BRCA2 population, 56.3 (52.3-58.7) for menopause
stratum, and 36.8 (34.9-41.4) for the ovulating population
(p < 0.0001, log-rank test). Women who underwent an oo-
phorectomy had a higher survival probability than those
who did not (p < 0.0001, log-rank test). At age 50 years,
probability (95% CI) of survival was 0.88 (0.82-0.95) for
those who had oophorectomy (102 women, 23 breast can-
cer events), versus 0.34 (0.30-0.40) for the others. At age
60 it was 0.70 (0.59-0.83) versus 0.11 (0.07-0.15). As in the
BRCA1 population, there was only one case of breast can-
cer after risk reducing mastectomy (out of 17 women
operated). Figure 1 shows Kaplan-Meier graphs for the
whole BRCA1/2 population, for the menopausal stage
strata, and for those who had/had not oophorectomy after
the diagnosis of an ovarian cancer.
When applying models (i) through (vi) and RSF on
the whole BRCA1 population, using the out-of-bag esti-
mator, average (st. dev.) 1 - c-index values of models
were (see Table 3), respectively, 0.468 (0.037), 0.221
(0.019), 0.504 (0.026), 0.238 (0.019), 0.222 (0.019), 0.236
(0.018), 0.243 (0.019). When applying models (i)
through (vi) and RSF on the whole BRCA2 population,
using the out-of-bag estimator, average (st. dev.) 1 - c-
index values of models were, respectively, 0.417 (0.021),
0.215 (0.018), 0.469 (0.028), 0.241 (0.019), 0.217 (0.018),
0.232 (0.019), 0.230 (0.019). The best model was therefore
(ii), including GPS and clinical/demographic variables.
The hypothesis of a lower difference in mean with respect
to model (ii) for all other models could be rejected, exceptTable 3 Average (st. dev.) 1 - c-index performance results
of cox proportional hazards and random survival forest
models as estimated by collating out-of-bag distributions
from 100 bootstrap runs
Model Average (st.dev.) 1 - c-index
BRCA1 BRCA2
(i) GPS 0.468 (0.037)* 0.417 (0.021)*
(ii) GPS + Clin./Demogr. 0.221 (0.019) 0.215 (0.018)
(iii) SNPs 0.504 (0.026)* 0.469 (0.028)*
(iv) SNPs + Clin./Demogr. 0.238 (0.019) 0.241 (0.019)
(v) Clin./Demogr. 0.222 (0.019) 0.217 (0.018)
(vi) all variables (by AIC) 0.236 (0.018) 0.232 (0.019)
Random survival forest (all variables) 0.243 (0.019) 0.230 (0.019)
*p < 0.0001 as compared to model (ii) by an adjusted t-test. Values in bold
show the best performance.for model (i) and (iii), which included only genetic vari-
ables (all p < 0.0001 for both BRCA1 and BRCA2, Stu-
dent’s t-test corrected for sample overlap from multiple
validation). Notably a re-calibrated SNP score, i.e. models
(iii) and (iv), did not perform as well as the GPS. Consist-
ent results were obtained by looking at the AUROC in the
1st, 2nd and 3rd quartiles of observation times. The
AUROC estimation was performed on a smaller out-of-
bag sample (333 out-of-bag instances) for computational
reasons. Figures 2 and 3 show c-index/AUROC graphs for
BRCA1/2 sets based on the out-of-bag estimator. Similar
figures were obtained when stratifying for the menopausal
stage (data not shown).
Tables 4 and 5 report relative hazards obtained by fit-
ting Cox model (ii) on BRCA1 and BRCA2 populations,
overall and stratified by menopausal stage. There was a
calendar year of birth effect, increasing the risk of can-
cer for both BRCA1/2 carrier cohorts (RH ranging from
1.06 to 1.08, p < 0.0005 across all strata). The Manchester
score had a protective effect in the BRCA1 menopause
stratum (RH = 0.35, p = 0.0006) and showed the same
trend in the whole BRCA1 population (RH = 0.8, p = 0.1),
but the RH directions were not consistent across all strata
as well as significance levels. The GPS score had a protect-
ive effect in the whole BRCA1 population and in the ovu-
lating strata (RH 0.76/0.58, p < 0.015), and was associated
to a higher hazard of breast cancer in the BRCA2 whole
population (RH = 1.33, p = 0.035).
The ovulating stratum (i.e. “not yet” in the meno-
pausal stage as from Tables 4 and 5) had a higher haz-
ard of breast cancer as compared to the first age
quartile of the menopausal stage stratum (i.e. women
entering the menopausal stage at ~40 years old). An
early age of menopause (first age quartile, ~40 years
old) was associated with a higher hazard of breast can-
cer as compared to an older age of menopause (yet a
higher hazard than the ovulating stratum), consistently
across all BRCA1/2 carrier types, in the whole popula-
tion and in the menopausal stage stratum. Note that
menopause may be happening within the same year a
chemotherapy was initiated right upon breast cancer
diagnosis, resulting de facto in competing events (as
diagnosis of menopause was given to the nearest year
of age). Women who had either oophorectomy had a
lower hazard as compared to those who had not (mast-
ectomy could not be properly assessed due to the low
number of events).
Finally, when fitting model (vi), i.e. feature-selected
Cox regression using a forward/backward stepwise heur-
istic driven by AIC, for both BRCA1/2 sets only the year
of birth, all the menopausal age stages (along with ovu-
lating stratum), and the oophorectomy variables were se-
lected in the final model (RH were in line with those
obtained from other models).
Figure 2 Model selection results for BRCA1 (upper panel) and BRCA2 (lower panel) data sets, comparing c-index performance of Cox
regression models (i) through (vi) and random survival forest (RSF). Boxplots drawn upon out-of-bag predictions (100 resampled sets).
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In this study we applied a robust model selection frame-
work composed of linear and non-linear statistical tech-
niques for survival analysis, with the objective to test the
predictive ability of existing risk scores for breast cancer
in a population of BRCA1/2 carriers, and to improve
over the current state-of-the-art, from the models based
on early genotyping and familial assessment to the most
recent SNP scoring, trying to combine both clinical/demographic information with high-resolution genetics.
Also, we assessed the incidence and the determinants of
breast cancer in the study population, and stratified the
analyses by the menopausal status.
RSF did not yield higher performance as compared to
CPH, even if for some of the data sets the proportional
hazard assumption was not met. Interestingly, the re-
calibration of GPS via the inclusion of SNPs in a CPH
did not produce a better model fit (in terms of c-index
Figure 3 Model selection results for BRCA1 (upper panel) and BRCA2 (lower panel) data sets, comparing AUROC performance of Cox
regression models (i) through (vi) and random survival forest (RSF). Time points correspond to the quartiles of the overall population
observation time distribution. Curves drawn upon out-of-bag predictions (15 resampled sets).
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our case, the c-index estimation through out-of-bag dis-
tributions may be a conservative choice, but robust to
over-training.This study further highlights the predictive ability of
GPS for BRCA2, showing an increased RH 1.33 (1.1-1.61)
in the whole population, although not significant at the
0.05 level in the menopausal/ovulating stage strata.
Table 4 Multivariable cox regression fit on BRCA1 data set, overall and stratified by menopausal stage, with covariate
set based on model (ii)
Variable
BRCA1
All subjects Menopause Ovulating
AIC = 3175 AIC = 765 AIC = 591
PH p-value < 0.0001 PH p-value = 0.0111 PH p-value = 0.5040
RH (95% CI) p-value RH (95% CI) p-value RH (95% CI) p-value
Year of birth 1.06 (1.05-1.08) <0.0001 1.06 (1.03-1.09) <0.0001 1.08 (1.04-1.11) <0.0001
Manchester score 0.8 (0.61-1.05) 0.1013 0.35 (0.19-0.64) 0.0006 1.56 (0.83-2.91) 0.1635
GPS 0.76 (0.61-0.95) 0.0151 0.88 (0.54-1.45) 0.6248 0.58 (0.37-0.9) 0.0148
BMI 1.02 (0.98-1.06) 0.3942 1.01 (0.94-1.07) 0.844 1.13 (1.02-1.25) 0.0229
Parity q2 vs. q1 1.32 (0.91-1.89) 0.1389 1.99 (0.91-4.37) 0.0846 0.72 (0.32-1.63) 0.4298
Parity q3 vs. q1 1.21 (0.8-1.82) 0.377 1.24 (0.52-2.96) 0.6246 0.85 (0.36-2.04) 0.7228
Parity q4 vs. q1 1.61 (1.01-2.56) 0.046 1.88 (0.65-5.44) 0.2434 1.21 (0.43-3.4) 0.724
Parity missing vs. q1 1.22 (0.43-3.52) 0.7066 N/A N/A 3.16 (0.34-28.9) 0.3089
Age of menarche q2 vs. q1 1.17 (0.82-1.67) 0.3914 1.14 (0.58-2.26) 0.6979 0.43 (0.17-1.07) 0.0695
Age of menarche q3 vs. q1 1.02 (0.67-1.54) 0.9345 1.02 (0.45-2.32) 0.9638 0.87 (0.45-1.71) 0.6918
Age of menarche q4 vs. q1 0.82 (0.55-1.23) 0.3437 1.34 (0.71-2.54) 0.3682 0.94 (0.4-2.16) 0.8772
Age of menarche missing vs. q1 1.12 (0.71-1.74) 0.6307 2.63 (0.86-8.03) 0.0902 1.49 (0.58-3.81) 0.4094
Age of menopause q2 vs. q1 0.37 (0.19-0.72) 0.0036 0.19 (0.09-0.43) <0.0001
Age of menopause q3 vs. q1 0.39 (0.22-0.7) 0.0015 0.21 (0.1-0.45) <0.0001
Age of menopause q4 vs. q1 0.33 (0.18-0.6) 0.0003 0.13 (0.06-0.28) <0.0001
Age of menopause missing vs. q1 0.64 (0.39-1.04) 0.0708
Age of menopause not yet* vs. q1 4.48 (2.74-7.33) <0.0001
Age of full-term pregnancy q2 vs. q1 1.22 (0.87-1.71) 0.2594 1.96 (0.98-3.91) 0.0576 1.06 (0.45-2.49) 0.8908
Age of full-term pregnancy q3 vs. q1 1.37 (0.96-1.96) 0.079 2.01 (0.94-4.32) 0.0734 2.06 (0.97-4.38) 0.0615
Age of full-term pregnancy q4 vs. q1 1.22 (0.81-1.84) 0.3512 2.8 (1.16-6.76) 0.0221 0.95 (0.34-2.64) 0.9163
Age of full-term pregnancy missing vs. q1 1.11 (0.7-1.79) 0.652 1.31 (0.45-3.8) 0.6245 0.98 (0.34-2.83) 0.9744
Age of full-term pregnancy not yet** vs. q1 2.17 (0.98-4.79) 0.0552 N/A N/A 2.69 (0.77-9.34) 0.1198
Oral contraception usage q2 vs. q1 0.64 (0.39-1.04) 0.0704 0.4 (0.18-0.9) 0.0263 1.14 (0.39-3.33) 0.8105
Oral contraception usage q3 vs. q1 1.07 (0.71-1.62) 0.7575 0.48 (0.23-1) 0.0495 4.77 (1.77-12.83) 0.002
Oral contraception usage q4 vs. q1 1 (0.65-1.54) 0.9936 0.98 (0.46-2.07) 0.9571 2.13 (0.82-5.54) 0.1211
Oral contraception usage missing vs. q1 1.1 (0.72-1.66) 0.6686 0.4 (0.19-0.87) 0.0207 3.94 (1.42-10.94) 0.0084
Mastectomy 0.04 (0.01-0.31) 0.0018 0.05 (0.01-0.39) 0.0044 N/A N/A
Oophorectomy 0.31 (0.16-0.58) 0.0003 0.3 (0.15-0.62) 0.0012 N/A N/A
N/A: could not be fit in the model; q1… q4: first to fourth age quartile, with the first being the youngest (~40 years old); *Ovulating; **Never had full term pregnancy.
Prosperi et al. BMC Medical Informatics and Decision Making 2014, 14:87 Page 8 of 11
http://www.biomedcentral.com/1472-6947/14/87Instead, for BRCA1 the effect of GPS was protective (RH=
0.76, p = 0.01) in the whole BRCA1 population and in the
ovulating stage stratum (also protective but not significant
at the 0.05 level in the menopausal stratum). Previous find-
ings of Ingham et al. [8] already pointed out the predictive
ability of 18 SNP GPS in BRCA2 but not BRCA1 carriers.
This significant association of GPS however was not sup-
ported when fitting the stepwise models, retaining only the
year of birth, the menopausal stage and the oophorectomy
variables (across all carrier types and strata). The age cohort
and oophorectomy had been previously associated with in-
creased and decreased risk of breast cancer, respectively[35,36]. We found that an later ages of menopause have a
lower hazard of breast cancer as compared to the first age
quartile, ~40 years old, which seems in contradiction with
previous results by Tyrer et al. [18], and being on the ovu-
lating stratum has a higher hazard than experiencing early
menopause. This is likely a model artefact, because the
menopause may happen (being induced) right after to the
initiation of a chemotherapy (i.e. competing events), and the
menopause age is given to the nearest year. In any case, as
women entering the menopausal stage early may be subject
to treatment for preserving fertility, this warrants further
investigation including a number of potential confounders.
Table 5 Multivariable cox regression fit on BRCA2 data set, overall and stratified by menopausal stage, with covariate
set based on model (ii)
Variable
BRCA2
All subjects Menopause Ovulating
AIC = 3137 AIC = 881 AIC = 475
PH p-value = 0.03497 PH p-value = 0.00125 PH p-value = 0.11892
RH (95% CI) p-value RH (95% CI) p-value RH (95% CI) p-value
Year of birth 1.07 (1.05-1.08) <0.0001 1.07 (1.04-1.11) <0.0001 1.06 (1.02-1.09) 0.0005
Manchester score 1.04 (0.76-1.43) 0.8048 1 (0.61-1.65) 0.9862 1.49 (0.56-3.98) 0.4228
GPS 1.33 (1.1-1.61) 0.0038 1.33 (0.93-1.91) 0.119 0.88 (0.51-1.51) 0.6416
BMI 0.99 (0.94-1.03) 0.5491 0.99 (0.92-1.06) 0.6694 1.03 (0.92-1.16) 0.5714
Parity q2 vs. q1 0.9 (0.66-1.24) 0.5307 1.4 (0.73-2.67) 0.3096 1.06 (0.38-2.99) 0.9083
Parity q3 vs. q1 0.89 (0.6-1.34) 0.5817 1.01 (0.46-2.21) 0.9808 1.51 (0.36-6.31) 0.5705
Parity q4 vs. q1 0.78 (0.47-1.28) 0.3182 0.9 (0.38-2.13) 0.8112 1.32 (0.34-5.12) 0.6914
Parity missing vs. q1 0.15 (0.06-0.38) <0.0001 N/A N/A N/A N/A
Age of menarche q2 vs. q1 1.36 (0.94-1.97) 0.1007 2.53 (1.47-4.35) 0.0008 1.57 (0.64-3.84) 0.3251
Age of menarche q3 vs. q1 1.39 (0.94-2.07) 0.0984 1.76 (0.95-3.27) 0.0742 2.43 (0.92-6.45) 0.074
Age of menarche q4 vs. q1 1.25 (0.83-1.88) 0.2822 1.51 (0.83-2.76) 0.1803 2.03 (0.79-5.25) 0.1422
Age of menarche missing vs. q1 2.32 (1.43-3.78) 0.0007 1.54 (0.18-13.15) 0.6947 1.06 (0.24-4.81) 0.9362
Age of menopause q2 vs. q1 1.16 (0.64-2.1) 0.6161 0.76 (0.39-1.48) 0.4188
Age of menopause q3 vs. q1 0.91 (0.51-1.63) 0.7511 0.63 (0.34-1.17) 0.1429
Age of menopause q4 vs. q1 0.9 (0.48-1.69) 0.7391 0.67 (0.33-1.37) 0.2762
Age of menopause missing vs. q1 1.03 (0.59-1.8) 0.9114
Age of menopause not yet* vs. q1 4.11 (2.41-7.01) <0.0001
Age of full-term pregnancy q2 vs. q1 1.55 (1.1-2.2) 0.0133 1.52 (0.82-2.81) 0.1825 1.96 (0.69-5.57) 0.2043
Age of full-term pregnancy q3 vs. q1 1.03 (0.71-1.49) 0.8902 0.94 (0.48-1.85) 0.8659 1.61 (0.62-4.19) 0.327
Age of full-term pregnancy q4 vs. q1 0.91 (0.62-1.33) 0.6154 1.96 (1.01-3.8) 0.0471 0.6 (0.21-1.71) 0.3371
Age of full-term pregnancy missing vs. q1 1.43 (0.95-2.15) 0.0822 1.16 (0.46-2.88) 0.7546 2.64 (0.68-10.25) 0.161
Age of full-term pregnancy not yet** vs. q1 16.5 (5.32-51.21) <0.0001 N/A N/A 19.2 (3.57-103.1) 0.0006
Oral contraception usage q2 vs. q1 1 (0.64-1.54) 0.9822 1.29 (0.67-2.48) 0.4473 0.84 (0.31-2.25) 0.7241
Oral contraception usage q3 vs. q1 1.67 (1.11-2.5) 0.0129 1.8 (0.94-3.46) 0.0774 1.45 (0.58-3.63) 0.4289
Oral contraception usage q4 vs. q1 1.34 (0.85-2.1) 0.2049 1.95 (0.92-4.11) 0.0814 0.85 (0.3-2.4) 0.7582
Oral contraception usage missing vs. q1 1.08 (0.71-1.63) 0.7282 0.9 (0.46-1.74) 0.7472 1.44 (0.58-3.59) 0.4294
Mastectomy 0.05 (0.01-0.39) 0.0038 N/A N/A N/A N/A
Oophorectomy 0.18 (0.11-0.29) <0.0001 0.22 (0.13-0.38) <0.0001 N/A N/A
N/A: could not be fit in the model; q1 … q4: first to fourth quartile, with the first being the youngest (~40 years old); *ovulating; **never had full term pregnancy
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http://www.biomedcentral.com/1472-6947/14/87Limitations of this study are in the usage of the c-
index as a measure of model performance, which pre-
sents a series of flaws [37-39], although our results were
confirmed using the AUROC estimator. Alternative
measures have been presented, like prediction error
curves [40] that may be employed as additional indica-
tors. Another limitation is that we did not fit the Cox
models using time-updated covariates (as for meno-
pausal stage or age of menarche, for instance) and this
may dilute their effect across all time, instead of calculat-
ing the hazard on specific time intervals.Conclusions
We exploited model selection in machine learning
towards the personalised diagnosis of breast cancer,
incorporating different domains of information in-
cluding genetics, clinical, and demographics. Given
the improvement in prediction performance obtained
by coupling a genetic progression score with clinical
and demographic markers, further investigation for
identifying both genetic and non-genetic factors
(along with their interactions in terms of epigenetics)
is warranted.
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